We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Gilead's revenue beat analysts' expectations in Q3 2018, despite falling behind last year's results, leading the company to boost its earnings expectations for the year.
Activists in the U.S. are asking authorities to break Gilead’s patents on Truvada in an effort to help end the HIV epidemic. Now, a court in the U.K. has done just that, potentially allowing for widespread use of generics as a ...
In a clean sweep, the two top executives at Gilead Sciences will step down at the end of this year, setting the struggling company up for an entirely new direction.